Literature DB >> 24817537

[New options in the treatment of acute heart failure].

A Link1, M Böhm.   

Abstract

Acute heart failure is defined as the acute onset of symptoms due to hear failure necessitating emergency therapy. The in-hospital mortality rate ranges up to 10 % and in cardiogenic shock is 50-70 %. In acute heart failure, rapid diagnosis and causal therapy are necessary to avoid cardiogenic shock. In cases of acute coronary syndromes, primary percutaneous intervention should be performed immediately. Medical and apparative treatment strategies focus on decreasing pulmonary congestion, afterload, and neurohormonal activation in order to improve hemodynamics and reduce symptoms of dyspnea. In contrast to chronic heart failure, no medical therapy has been able to reduce mortality rates in acute heart failure. However, new medical therapies should at least improve clinical symptoms of congestion and favorably reduce cardiovascular events, re-hospitalization, and mortality rates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24817537     DOI: 10.1007/s00108-013-3426-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Authors:  Cynthia Binanay; Robert M Califf; Vic Hasselblad; Christopher M O'Connor; Monica R Shah; George Sopko; Lynne W Stevenson; Gary S Francis; Carl V Leier; Leslie W Miller
Journal:  JAMA       Date:  2005-10-05       Impact factor: 56.272

2.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

Review 3.  Definition and epidemiology of acute heart failure syndromes.

Authors:  Markku S Nieminen; Veli-Pekka Harjola
Journal:  Am J Cardiol       Date:  2005-09-19       Impact factor: 2.778

4.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

Review 5.  Acute heart failure: lessons learned so far.

Authors:  Jonathan G Howlett
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

6.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

7.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Authors:  John G F Cleland; John R Teerlink; Roxy Senior; Evgeny M Nifontov; John J V Mc Murray; Chim C Lang; Vitaly A Tsyrlin; Barry H Greenberg; Jamil Mayet; Darrel P Francis; Tamaz Shaburishvili; Mark Monaghan; Mitchell Saltzberg; Ludwig Neyses; Scott M Wasserman; Jacqueline H Lee; Khalil G Saikali; Cyril P Clarke; Jonathan H Goldman; Andrew A Wolff; Fady I Malik
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

8.  Update on the Management of Acute Decompensated Heart Failure.

Authors:  David T Majure; John R Teerlink
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10-06

9.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

Authors:  Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

10.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.

Authors:  Mihai Gheorghiade; William T Abraham; Nancy M Albert; Barry H Greenberg; Christopher M O'Connor; Lilin She; Wendy Gattis Stough; Clyde W Yancy; James B Young; Gregg C Fonarow
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

View more
  1 in total

1.  Analyzing Dynamic Changes of Laboratory Indexes in Patients with Acute Heart Failure Based on Retrospective Study.

Authors:  Yurong Wang; Lei Fu; Qian Jia; Hao Yu; Pengjun Zhang; Chunyan Zhang; Xueliang Huang; Kunlun He; Yaping Tian
Journal:  Biomed Res Int       Date:  2016-04-06       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.